READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma.

ABSTRACT:

Background

Avelumab first-line (1L) maintenance is recommended as the standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without disease progression following 1L platinum-based chemotherapy (PBC). We report results from READY, a real-world study of avelumab 1L maintenance in an Italian compassionate use program (CUP).

Patients and methods

In this prospective, noninterventional CUP, avelumab was provided on physician's request to patients with la/mUC without disease progression following four to six cycles of 1L PBC, after approval by the local ethics committees, per Italian compassionate use regulations.

Results

Between January 2021 and March 2022, 414 patients received avelumab 1L maintenance and were assessable for surviv

SUBMITTER: Antonuzzo L 

PROVIDER: S-EPMC12836724 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature